vs
NextPlat Corp（NXPL）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
NextPlat Corp的季度营收约是Protalix BioTherapeutics, Inc.的1.4倍（$12.8M vs $9.1M），NextPlat Corp净利率更高（-40.2% vs -60.3%，领先20.2%），NextPlat Corp同比增速更快（-21.1% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-339.0K），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -14.4%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
NXPL vs PLX — 直观对比
营收规模更大
NXPL
是对方的1.4倍
$9.1M
营收增速更快
NXPL
高出28.8%
-49.9%
净利率更高
NXPL
高出20.2%
-60.3%
自由现金流更多
PLX
多$2.0M
$-339.0K
两年增速更快
PLX
近两年复合增速
-14.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $12.8M | $9.1M |
| 净利润 | $-5.1M | $-5.5M |
| 毛利率 | 14.3% | 49.4% |
| 营业利润率 | -28.9% | -51.1% |
| 净利率 | -40.2% | -60.3% |
| 营收同比 | -21.1% | -49.9% |
| 净利润同比 | -70.6% | -184.8% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NXPLPLX
| Q4 25 | $12.8M | $9.1M | ||
| Q3 25 | $13.8M | $17.9M | ||
| Q2 25 | $13.2M | $15.7M | ||
| Q1 25 | $14.5M | $10.1M | ||
| Q4 24 | $16.2M | $18.2M | ||
| Q3 24 | $15.4M | $18.0M | ||
| Q2 24 | $17.0M | $13.5M | ||
| Q1 24 | $17.5M | — |
净利润NXPLPLX
| Q4 25 | $-5.1M | $-5.5M | ||
| Q3 25 | $-2.2M | $2.4M | ||
| Q2 25 | $-1.8M | $164.0K | ||
| Q1 25 | $-1.3M | $-3.6M | ||
| Q4 24 | $-3.0M | $6.5M | ||
| Q3 24 | $-4.2M | $3.2M | ||
| Q2 24 | $-5.3M | $-2.2M | ||
| Q1 24 | $-1.5M | — |
毛利率NXPLPLX
| Q4 25 | 14.3% | 49.4% | ||
| Q3 25 | 19.9% | 53.4% | ||
| Q2 25 | 21.8% | 62.5% | ||
| Q1 25 | 23.8% | 19.1% | ||
| Q4 24 | 16.8% | 78.7% | ||
| Q3 24 | 23.2% | 53.4% | ||
| Q2 24 | 34.5% | 29.8% | ||
| Q1 24 | 27.8% | — |
营业利润率NXPLPLX
| Q4 25 | -28.9% | -51.1% | ||
| Q3 25 | -14.5% | 11.9% | ||
| Q2 25 | -13.8% | 7.5% | ||
| Q1 25 | -10.2% | -41.0% | ||
| Q4 24 | -14.1% | 39.6% | ||
| Q3 24 | -52.1% | 22.2% | ||
| Q2 24 | -64.1% | -18.0% | ||
| Q1 24 | -10.5% | — |
净利率NXPLPLX
| Q4 25 | -40.2% | -60.3% | ||
| Q3 25 | -15.9% | 13.2% | ||
| Q2 25 | -13.5% | 1.0% | ||
| Q1 25 | -9.2% | -35.8% | ||
| Q4 24 | -18.6% | 35.6% | ||
| Q3 24 | -27.4% | 18.0% | ||
| Q2 24 | -31.3% | -16.4% | ||
| Q1 24 | -8.5% | — |
每股收益（稀释后）NXPLPLX
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | $-0.05 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-0.22 | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | $-0.08 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.7M | $14.7M |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $17.3M | $48.2M |
| 总资产 | $27.5M | $82.3M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资NXPLPLX
| Q4 25 | $13.7M | $14.7M | ||
| Q3 25 | $13.9M | $13.6M | ||
| Q2 25 | $16.6M | $17.9M | ||
| Q1 25 | $17.7M | $19.5M | ||
| Q4 24 | $20.0M | $19.8M | ||
| Q3 24 | $20.4M | $27.4M | ||
| Q2 24 | $24.9M | $23.4M | ||
| Q1 24 | $23.5M | — |
总债务NXPLPLX
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.4M | — |
股东权益NXPLPLX
| Q4 25 | $17.3M | $48.2M | ||
| Q3 25 | $21.4M | $52.9M | ||
| Q2 25 | $23.5M | $49.9M | ||
| Q1 25 | $25.3M | $45.2M | ||
| Q4 24 | $27.3M | $43.2M | ||
| Q3 24 | $22.5M | $32.4M | ||
| Q2 24 | $26.5M | $28.6M | ||
| Q1 24 | $31.2M | — |
总资产NXPLPLX
| Q4 25 | $27.5M | $82.3M | ||
| Q3 25 | $30.0M | $82.3M | ||
| Q2 25 | $31.0M | $78.5M | ||
| Q1 25 | $35.2M | $73.9M | ||
| Q4 24 | $37.1M | $73.4M | ||
| Q3 24 | $41.1M | $61.6M | ||
| Q2 24 | $51.5M | $91.5M | ||
| Q1 24 | $65.1M | — |
负债/权益比NXPLPLX
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-302.0K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-339.0K | $1.6M |
| 自由现金流率自由现金流/营收 | -2.6% | 17.8% |
| 资本支出强度资本支出/营收 | 0.3% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-13.6M |
8季度趋势，按日历期对齐
经营现金流NXPLPLX
| Q4 25 | $-302.0K | $2.0M | ||
| Q3 25 | $-2.7M | $-3.7M | ||
| Q2 25 | $-1.0M | $-5.2M | ||
| Q1 25 | $-2.1M | $-5.1M | ||
| Q4 24 | $-476.0K | $4.0M | ||
| Q3 24 | $-4.6M | $4.1M | ||
| Q2 24 | $2.3M | $-3.6M | ||
| Q1 24 | $-2.7M | — |
自由现金流NXPLPLX
| Q4 25 | $-339.0K | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-1.1M | $-5.7M | ||
| Q1 25 | $-2.1M | $-5.4M | ||
| Q4 24 | $-508.0K | $3.6M | ||
| Q3 24 | $-4.7M | $4.0M | ||
| Q2 24 | $2.2M | $-3.8M | ||
| Q1 24 | $-2.7M | — |
自由现金流率NXPLPLX
| Q4 25 | -2.6% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -8.0% | -36.2% | ||
| Q1 25 | -14.3% | -53.0% | ||
| Q4 24 | -3.1% | 19.6% | ||
| Q3 24 | -30.6% | 22.4% | ||
| Q2 24 | 13.2% | -28.1% | ||
| Q1 24 | -15.7% | — |
资本支出强度NXPLPLX
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.4% | 1.3% | ||
| Q1 24 | 0.4% | — |
现金转化率NXPLPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
